Navigation Links
ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
Date:4/2/2008

DENVER and GOLDEN, Colo., April 2, 2008 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today that it will exhibit for the first time at the 14th Annual Conference and Exhibition of the Society for Biomolecular Sciences (SBS) in St. Louis, April 6 - 10, 2008.

"We are extremely pleased to support the advancement of the science of drug discovery by exhibiting at the SBS meeting, especially as it is a non-profit forum. This is our first in what I foresee as a multiple year commitment to supporting this cutting edge area of basic and applied pharmaceutical research," said Ken Wilczek, President of ABR. "It is truly a privilege to be involved with these top-level, dedicated institutions and talented individuals in the furtherance of innovative drug discovery research that could lead to potentially life-saving therapies," continued Mr. Wilczek. ABR-Affinity BioReagents' high quality portfolio of monoclonal and polyclonal antibodies, recombinant proteins, siRNA and custom antibody and peptide production services are already in use by every major research institution, government agency, university, and pharmaceutical company in the world today.

"Feedback from leading researchers in the areas of cancer biology and disease research, especially arthritis and inflammation, is invaluable to us in determining strategic direction. The international character of this audience will enable ABR to collaborate on a meaningful level with the most influential scientists in the world," noted Mr. Wilczek. ABR-Affinity BioReagents will be located at booth #220.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).

With more than 35,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry -- research antibodies that are 100% quality guaranteed or your money back -- with no questions asked.

Utilizing a distribution network encompassing over 55 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
2. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
3. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
4. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
5. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
6. Biotechnology Leader to Exhibit at Upcoming Trade Show
7. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
8. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
9. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
10. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
11. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):